The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

• Conditions: Metabolic Diseases; Chronic Kidney Disease

• Registration Number: NCT01317186
• Lead Sponsor: Ankara Education and Research Hospital

Brief Summary

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2011-03
• Study Start: 2011-03
• Study First Submitted: 2011-03-16
• Study First Submitted QC: 2011-03-16
• Last Update Submitted: 2011-03-16
• Study First Posted: 2011-03-17
• Last Update Posted: 2011-03-17

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• between ages of 18 - 65 years old
• chronic kidney disease of stage 2-4

Exclusion Criteria

• presence of diabetes mellitus or ischemic hearth disease
• taking vitamin d therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Ankara Education and Research Hospital; 🇹🇷 Ankara, Turkey